FlowCAT offers flexible fixed-bed hydrogenation

Published: 22-Mar-2010
Manufacturing

Bench-top reactor produces results from millilitres of product

FlowCAT offers flexible fixed-bed hydrogenation
HEL, an international group of companies supplying process tools for the pharmaceutical industry, has introduced the FlowCAT continuous flow bench-top reactor, which is said to be a flexible and cost-effective choice in lab-scale fixed-bed hydrogenation.

HEL, headquartered in Borehamwood, Hertfordshire, UK, has developed a system that delivers high-pressure flow chemistry, with the flexibility to tune hydrogenation conditions to suit the chemistry.

The system design allows for rapid screening of process conditions, which is useful in the early stage generation of API intermediates, where the behaviour and chemistry of the species may be an unknown.

The FlowCAT system is capable of producing results from just a few millilitres of product, but retains the ability to ramp up production volumes once ideal conditions are identified.

At the heart of the system is a tubular reactor with a standard 3mL or 12mL isothermal reaction zone. The system operates up to 400°C and 200Bar. Any heterogeneous catalyst can be used and users can pack their own columns. The wide-bore reactor removes any propensity for blockages and further extends the reliability of the system, the company says.

See more

You may also like

Manufacturing
Patented device reinvents Solid Phase Extraction

Patented device reinvents Solid Phase Extraction

Read more
Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition

Trending Articles

  1. Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
  2. FDA inspection readiness: Preparing for surveillance and pre-approval inspections Preparing pharma and biotech teams for continuous FDA inspection readiness, mock inspections and proactive regulatory risk management
  3. Hovione to install first ConsiGma CDC Flex continuous tableting line in US The CDMO is investing $35m in a next-generation continuous tableting line at its 89 Twin Rivers facility in New Jersey, creating an integrated US pathway from spray-dried amorphous solid dispersions to commercial tablet production
  4. SCHOTT Pharma makes decarbonisation measurable Validated carbon footprint tool supports informed Scope 3 reduction decisions for pharmaceutical packaging
  5. FDA Form 483 explained: responding to findings and managing regulatory risk Explore what a Form FDA 483 means, how to respond within 15 business days, assess patient risk, address observations and understand how FDA evaluates responses and inspection outcomes

You may also like

Manufacturing
Patented device reinvents Solid Phase Extraction

Patented device reinvents Solid Phase Extraction

Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Manufacturing
Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's 10.6-hour half-life
Manufacturing
Lonza advances aseptic spray drying for high-dose biologics

Lonza advances aseptic spray drying for high-dose biologics

This new technology platform addresses stability, concentration, and delivery challenges in biologics, including new modalities
Manufacturing
Catalent launches ten-month gene-to-drug substance programme for complex biologics

Catalent launches ten-month gene-to-drug substance programme for complex biologics

The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten
Design & Build
Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite

Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite

The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
Manufacturing
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
Manufacturing
Why your coating process is less consistent than you think - and what to do about it

Why your coating process is less consistent than you think - and what to do about it

Tablet coating defects rarely begin at the coating stage. In this live webinar, industry expert Fred Rowley examines the upstream variables - suspension handling, spray-rate stability, gun pattern verification - that determine whether a coating process performs consistently at scale
Subscribe now